Ryan Bleeks
CEO
Visiox Pharmaceuticals
Finding Unconventional Ways to Achieve Results
Ryan Bleeks as CEO of Visiox Pharmaceuticals is single-handedly leading the development and anticipated commercialization of PDP-716 later this year. PDP-716 (0.35% brimonidine tartrate suspension) will be the first and only once-daily alpha agonist for the treatment of elevated intraocular pressure in glaucoma patients. PDP-716 has the potential to disrupt the significant market share that other alpha agonists, such as Alphagan, have established over the last 30+ years.
Ryan has taken an unconventional approach in leading Visiox Pharma to the commercialization of its first product by partnering with 27 of the most influential KOLs in ophthalmology as stakeholders of Visiox. His ability to bring together such an elite group of physicians is a true testament to his leadership skills and the trust he’s earned within the ophthalmic community.
Previously, as VP of Sales at RVL, he developed a strategic plan for the direct and virtual purchase program for Upneeq across the United States, developed a career development program for sales professionals and district managers, and built a business plan for sales professionals to deliver key performance indicators (KPIs) that yielded an 800% increase in eight months.
As National Sales Director at Sun, Ryan was responsible for a budget in excess of $80 million and led a successful launch of Xelpros, a novel prostaglandin for the treatment of open-angle glaucoma. As part of the strategy, he developed and executed a disruptive “cash model” for the brand. Additionally, he initiated and led a major reorganization of the commercial team based on evaluations in collaboration with McKinsey & Company that resulted in nearly doubling Sun’s revenue, from $59.8 million in 2018 to $102.6 million in 2019.
Much of Ryan’s success can be attributed to his willingness to trust his instincts, even if it goes against traditional pharma leadership strategies, and his relentless pursuit of finding innovative solutions to everyday business challenges.
